Ann Hematol (2017) 96:1573–1575 DOI 10.1007/s00277-017-3044-4 LETTER TO THE EDITOR In Burkitt lymphoma patients who relapse after induction with a short-intensive chemoimmunotherapy protocol, aggressive salvage chemotherapy therapy is ineffective: a single-center retrospective study 1 1 2 Martin Cremer & Mark-Alexander Schwarzbich & Tilman Schöning & 1 1 1 Katharina Lisenko & Anthony D. Ho & Mathias Witzens-Harig Received: 29 January 2017 /Accepted: 4 June 2017 /Published online: 16 June 2017 Springer-Verlag GmbH Germany 2017 Dear Editor, Therefore, we retrospectively analyzed the electronic Burkitt lymphoma (BL) is a highly aggressive non-hodgkin records of all patients (n = 38) who were newly diagnosed lymphoma (NHL) representing about 1% of mature NHLs . with Burkitt lymphoma, Burkitt-like lymphoma, B-cell The German Multicenter Study Group for Adult ALL con- lymphoma unclassifiable with features intermediate be- ducted the multicenter GMALL-B-ALL/NHL2002 trial, tween DLBCL, and Burkitt lymphoma (BCLU) or which used a short-intensive protocol based on rituximab, Burkitt leukemia between 2003 and 2013 in our institu- high-dose methotrexate, and triple intrathecal therapy, with a tion and were treated with curative intent. Patients were reduced regimen for patients >55 years old. This trial reported enrolled in the GMALL-B-ALL/NHL2002 trial if eligible an 88% complete response (CR)
Annals of Hematology – Springer Journals
Published: Jun 16, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera